Initiation of Coverage: Steris plc Overlooked, Defensive Compounder. Buy at $275 PT.

Research evidence excerpt

Initiation of Coverage: Steris plc Overlooked, Defensive Compounder. Buy at $275 PT.

Global Research

28 July 2026ab

Initiation of Coverage

EquitiesSteris plc

Overlooked, Defensive Compounder. Buy at United States

$275 PT. Medical Supplies

12-month rating Buy

Prior : No Rating

12m price target US$275.00

Durable Compounder Overlooked Due to Timing Dynamics Rather than

Prior :

Demand Issues

We are initiating on Steris with a Buy rating and $275 PT. STE has been a name that we Price (24 Jul 2026) US$210.64

believe investors have misunderstood given several dynamics that muddy the bigger RIC: STE.N BBG: STE US

picture: a capex cycle that could be perceived as value destructive but is actually moat

Trading data and key metrics

widening, and an Applied Sterilization Technologies (AST) segment whose recent

deceleration reflects customer destocking rather than weak demand/competitive 52-wk range US$268.65-199.40

erosion. When looking beyond the temporal dynamics, STE is a highly resilient business Market cap. US$20.7b

that is embedded at the core of hospital infrastructure and into manufacturers' Shares o/s 98.1m (COM)

workflows. It is highly difficult to displace and in our view more durable than current Free float 99%

valuation implies (our reverse DCF suggests 5% vs us at 7% and Street at 7% over FY26- Avg. daily volume ('000) 236

29). We see a positive risk/reward as destocking normalizes and capex cycle matures. Avg. daily value (m) US$49.8

Common s/h equity (03/27E) US$7.50b

Our Analysis Conveys that Worries About the AST Business are Misplaced, P/BV (03/27E) 2.7x

Contribution Margin Lever Underappreciated Net debt to EBITDA (03/27E) 0.8x

Our analysis suggests that concerns around AST demand are overdone as end-market

EPS (UBS, diluted) (USD)